The overexpression of NPRL2 in NPRL2-deficient and cisplatin-resistant NSCLC cells reactivates cellular response to cisplatin and promotes tumor suppression activity in vitro and in mouse models [74]. This evidence concerns the gene NPRL2 and non-small cell lung carcinoma.